Ponikowski P, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Eur Heart J. 2016; 37(27):2129-2200.
Mozaffarian D, Benjamin EJ, Go AS, et al. Heart Disease and Stroke Statistics—2016 Update: A report from the American Heart Association. Circulation. 2015; 133:e38-e360.
Weir LM, Pfuntner A, Maeda J, et al. HCUP facts and figures: statistics on hospital-based care in the United States, 2009. Rockville, MD: Agency for Healthcare Research and Quality, 2011.
Zannad F, et al. Heart failure burden and therapy. Europace. 2009; 11:v1-v9.
Mosterd A, Hoes AW. Clinical epidemiology of heart failure. Heart. 2007; 93:1137–46
Tavazzi L, et al. Nationwide survey on acute heart failure in cardiology ward services in Italy. Eur Heart J. 2006; 27:1207–15.
Garty M, et al. The management, early and one year outcome in hospitalized patients with heart failure: a national Heart Failure survey in Israel. Isr Med Assoc J. 2007; 9:227–33
Bui AL, et al. Epidemiology and risk profile of heart failure. Nat Rev Cardiol 2011; 8(1): 30–41.
Loehr LR, et al. Heart failure incidence and survival (from the Atherosclerosis Risk in Communities study). Am J Cardiol. 2008; 101:1016–1022.
Bueno H, et al. Trends in length of stay and short-term outcomes among Medicare patients hospitalized for heart failure: 1993-2008. JAMA. 2010; 303(21):2141–2147
Gheorghiade M, et al. Systolic blood pressure at admission, clinical characteristics, and outcomes in patients hospitalized with acute heart failure. JAMA. 2006; 296:2217–2226.
National heart failure audit: April 2010 – March 2011, NICOR and The British Society for Heart Failure, commissioned by the Healthcare Quality Improvement.
O’Connor M, et al. Causes of death and rehospitalization in patients hospitalized with worsening heart failure and reduced left ventricular ejection fraction: Results from efficacy of vasopressin antagonism in heart failure outcome study with tolvaptan (EVEREST) program. American Heart Journal. 2010; 159(5): 842-849.
Hunt S, et al. 2009 focused update incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation. 2009; 119:e391-e479.
Du X, et al. Cardiovascular effects of relaxin: from basic service to clinical therapy. Nat. Rev. Cardiol. 2010; 7:48-58.
Teichman S, et al. Relaxin, a pleiotropic vasodilator for the treatment of heart failure. Heart Fail Rev. 2009; 14:321-329.
Teichman SL, et al. Relaxin: Review of biology and potential role in treating heart failure. Curr Heart Fail Rep. 2010; 7:75-82.